Pediatrix Medical Group Inc

MD is in a Stage 2 advancing uptrend with rising EMAs and the 50 DMA providing dynamic support. The recent corrective pullback held at the 21 EMA and 50 DMA, repairing the 9/21 EMA structure and attracting supportive volume on the bounce. Short-term price is now pulling into rising EMAs without exhaustion, offering a favorable buying opportunity near structural support under the Growth at Reasonable Price strategy.

• ↑Q1 adj. EBITDA $58M beats estimates; revenue +3% YoY driven by pricing
• ↑Executed $21M buybacks; cash >$200M and net debt ~$385M, leverage ~1.3x
• ↓Same-unit volumes fell, notably in NICU, risking future revenue growth